INVIVYD, INC. (IVVD) Operating Margin
- Operating margin · 12 months: Value -192.81%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -192.81% | Operating income / revenue. Period ending 2026-06-30. $-112.53M ÷ $58.37M × 100 ≈ -192.81% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -112.53M USD | Operating Income (Loss) |
| Revenue | 58.37M USD | |
| Cost of products and services | (m) | |
| Research and development | 78.19M USD | Research and Development Expense |
| Selling, general and administration | 88.17M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-112.53M | $58.37M | (m) | $78.19M | $88.17M | -192.81% |
| 2026-03-31 | $-81.77M | $55.87M | (m) | $58.40M | $75.30M | -146.38% |
| 2025-12-31 | $-55.56M | $53.43M | (m) | $38.31M | $66.93M | -103.99% |
| 2025-09-30 | $-62.23M | $50.04M | (m) | $46.17M | $62.77M | -124.37% |
| 2025-06-30 | $-113.52M | $46.21M | (m) | $95.97M | $60.71M | -245.67% |
| 2025-03-31 | $-147.71M | $36.69M | (m) | $116.73M | $65.21M | -402.61% |
| 2024-12-31 | $-176.88M | $25.38M | (m) | $137.25M | $63.39M | -696.80% |
| 2024-09-30 | $-234.40M | (m) | (m) | $181.61M | $64.06M | (m) |
| 2024-06-30 | $-215.15M | (m) | (m) | $149.33M | $63.99M | (m) |
| 2024-03-31 | $-219.78M | (m) | (m) | $162.62M | $53.01M | (m) |
| 2023-12-31 | $-212.76M | (m) | (m) | $158.66M | $49.13M | (m) |
| 2023-09-30 | $-184.22M | (m) | (m) | $116.31M | $44.56M | (m) |
| 2023-06-30 | $-188.49M | (m) | (m) | $120.87M | $44.87M | (m) |
| 2023-03-31 | $-186.36M | (m) | (m) | $114.38M | $49.38M | (m) |
| 2022-12-31 | $-248.03M | (m) | (m) | $179.21M | $47.04M | (m) |
| 2022-09-30 | $-282.91M | (m) | (m) | $227.72M | $51.19M | (m) |
| 2022-06-30 | $-296.00M | (m) | (m) | $242.85M | $49.15M | (m) |
| 2022-03-31 | $-288.94M | (m) | (m) | $240.89M | $41.54M | (m) |
| 2021-12-31 | $-226.91M | (m) | (m) | $182.89M | $36.52M | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |